KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuances
Ratios

Amneal Pharmaceuticals (AMRX) EBIAT (2017 - 2026)

Amneal Pharmaceuticals has reported EBIAT over the past 9 years, most recently at $35.1 million for Q4 2025.

  • For Q4 2025, EBIAT rose 212.85% year-over-year to $35.1 million; the TTM value through Dec 2025 reached $97.7 million, up 183.56%, while the annual FY2025 figure was $72.1 million, 161.65% up from the prior year.
  • EBIAT for Q4 2025 was $35.1 million at Amneal Pharmaceuticals, up from $2.4 million in the prior quarter.
  • Over five years, EBIAT peaked at $35.6 million in Q2 2025 and troughed at -$240.1 million in Q2 2022.
  • A 5-year average of -$16.3 million and a median of $1.1 million in 2024 define the central range for EBIAT.
  • Biggest five-year swings in EBIAT: crashed 2717.38% in 2023 and later surged 1618.59% in 2025.
  • Year by year, EBIAT stood at -$20.5 million in 2021, then skyrocketed by 118.42% to $3.8 million in 2022, then crashed by 2717.38% to -$98.6 million in 2023, then skyrocketed by 68.49% to -$31.1 million in 2024, then skyrocketed by 212.85% to $35.1 million in 2025.
  • Business Quant data shows EBIAT for AMRX at $35.1 million in Q4 2025, $2.4 million in Q3 2025, and $35.6 million in Q2 2025.